SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ipca Laboratories - Quaterly Results

14 Feb 2023 Evaluate
A fair growth of 7.85% in the revenue at Rs. 14327.90 millions was reported in the December 2022 quarter as compared to Rs. 13284.70 millions during year-ago period.The Company to register a -44.87%  fall in the net profit for the quarter ended December 2022.Operating Profit reported a sharp decline to 2392.90 millions from 3247.60 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202212 202112 % Var 202212 202112 % Var 202203 202103 % Var
Sales 14327.90 13284.70 7.85 43869.50 42309.10 3.69 53993.60 51391.60 5.06
Other Income 253.00 132.40 91.09 807.00 419.20 92.51 561.30 622.40 -9.82
PBIDT 2392.90 3247.60 -26.32 8240.80 11064.40 -25.52 12996.70 15758.20 -17.52
Interest 104.30 12.70 721.26 262.30 40.00 555.75 72.10 81.40 -11.43
PBDT 2288.60 3234.90 -29.25 7978.50 11024.40 -27.63 12924.60 15676.80 -17.56
Depreciation 570.30 512.50 11.28 1653.60 1517.10 9.00 2041.00 1877.20 8.73
PBT 1718.30 2722.40 -36.88 6324.90 9507.30 -33.47 10883.60 13799.60 -21.13
TAX 515.60 540.70 -4.64 2006.20 1902.00 5.48 2174.20 2391.90 -9.10
Deferred Tax 1.60 64.50 -97.52 156.20 239.00 -34.64 201.40 -57.90 -447.84
PAT 1202.70 2181.70 -44.87 4318.70 7605.30 -43.21 8709.40 11407.70 -23.65
Equity 253.70 253.70 0.00 253.70 253.70 0.00 253.70 253.70 0.00
PBIDTM(%) 16.70 24.45 -31.68 18.78 26.15 -28.17 24.07 30.66 -21.50

Ipca Laboratories Share Price

1563.70 19.75 (1.28%)
06-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1850.40
Dr. Reddys Lab 1310.50
Cipla 1365.25
Zydus Lifesciences 939.10
Lupin 2442.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×